



**CASE STUDY:**  
**Gastrointestinal**

**GLOBAL BIOTECH  
RANDOMIZED 40%  
OF THE TARGET  
POPULATION IN 1/3  
OF TRADITIONAL  
RECRUITMENT TIME**

Trialbee's Smart Patient Matching  
saves 3 months in recruitment efforts

 **trialbee**

## Challenge

A global biotech initiated a phase IIb orphan drug study for the treatment of chronic ulcerative colitis.

Study protocol originally accounted for randomizing 120 patients across 40 investigator sites in six EU countries. Full enrollment was expected after 14 months of campaigning.

However, after deploying traditional recruitment methods, the sponsor met only 60% of its patient enrollment target, and extended the recruitment window an additional six months.

## Solution


Trialbee partnered with the biotech to close the enrollment gap and move the study forward as planned.

Highly-targeted patients from the public domain that were a good match for this rare disease study were easily identified using real-time analytics driven by Trialbee's Smart Patient Matching solution. Patients who qualified via an online questionnaire were subsequently screened by telephone by a professionally-trained, multilingual nurse panel to ensure each respective patient was indeed a high-quality referral suitable for randomization.

## Outcomes

Deploying Trialbee resulted in a 3-month savings in recruitment efforts. 40% of patients were randomized in just 1/3 of the full recruitment period.

Original projections estimated 12 months to enroll the required number of patients using traditional



### STUDY OVERVIEW

- Phase IIb study for severe chronic ulcerative colitis
- 40 investigator sites across 6 EU countries
- 120 patient-randomization target
- 14-month targeted recruitment timeline


### OUTCOME

- Randomized 40% of target population in only 1/3 of the full recruitment period
- Saved 3 months of recruitment efforts
- 165 patients referred through Trialbee

methods. However, the biotech enrolled less than 50 patients after 10 months, and extended its enrollment timeline to 19 months.

Trialbee partnered with the biotech to implement digital campaigning and get recruitment on track. The study met its enrollment target in 16 months, saving 3 months of recruitment efforts. However, if Trialbee had been deployed at study start, the biotech could have enrolled patients in 11 months, saving over 5 months of recruitment efforts.

Additionally, site burden was reduced through e-screening and nurse panel evaluations of referred patients. Only highly-qualified patients were referred and activated at each site, freeing site staff to focus on mission-critical tasks and enabling a superior experience for sites and patients.



## Trialbee Smart Patient Matching

Seamless patient recruitment experience powered by real-time analytics. For more information or to schedule a demo, email us at [solutions@trialbee.com](mailto:solutions@trialbee.com) or visit us at [trialbee.com](http://trialbee.com).

**40%**

40% patients randomized  
in 1/3 of traditional  
recruitment period

**3 Months**

3 months savings of  
recruitment time

**165**

165 patients referred

**120**

120 patients randomized  
and enrolled

